What Is the Evidence for the Use of Botulinum Toxin in Idiopathic Detrusor Overactivity?

被引：0
作者：
Mangera A. [1 ]
Chapple C.R. [2 ]
机构：
[1] Department of Urology Research, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield
[2] Royal Hallamshire Hospital, Sheffield, S10 2JF, H26, H-Floor, Glossop Road
来源：
Current Bladder Dysfunction Reports | 2011年 / 6卷 / 2期
关键词：
Botulinum toxin; Idiopathic detrusor overactivity; Overactive bladder;
D O I：
10.1007/s11884-011-0088-5
中图分类号：
学科分类号：
摘要：
There is growing evidence to support the use of botulinum toxin (BTX) in idiopathic detrusor overactivity. However, BTX remains off label for this purpose. In this commentary, we review the current status of the literature discussing the evidence for efficacy and safety of BTX. In addition, we present the data regarding the preparation, dose, and administration of BTX. As an emerging treatment, high-level evidence exists for the use of BTX in patients with idiopathic detrusor overactivity; however, details about the optimum number of injection sites and injection volume remain to be answered. In addition, long-term data regarding the effect of repeated injections requires further study. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：70 / 73
页数：3
相关论文
共 29 条
  • [1] Dykstra D.D., Sidi A.A., Scott A.B., Pagel J.M., Goldish G.D., Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients, J Urol, 139, pp. 919-922, (1988)
  • [2] Schurch B., Schmid D.M., Stohrer M., Treatment of neurogenic incontinence with botulinum toxin A, N Engl J Med, 342, (2000)
  • [3] Kuo H.C., Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents, Urology, 63, pp. 868-872, (2004)
  • [4] Kumar V., Chapple C.C., Chess-Williams R., Characteristics of adenosine triphosphate [corrected] release from porcine and human normal bladder, J Urol, 172, pp. 744-747, (2004)
  • [5] Apostolidis A., Dasgupta P., Fowler C.J., Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity, Eur Urol, 49, pp. 644-650, (2006)
  • [6] Apostolidis A., Popat R., Yiangou Y., Cockayne D., Ford A.P., Davis J.B., Et al., Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity, J Urol, 174, pp. 977-982, (2005)
  • [7] Giannantoni A., Di Stasi S.M., Nardicchi V., Zucchi A., Macchioni L., Bini V., Et al., Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity, J Urol, 175, pp. 2341-2344, (2006)
  • [8] Apostolidis A., Popat R., Yiangou Y., Cockayne D., Ford A.P., Davis J.B., Et al., Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity, J Urol, 174, pp. 977-982, (2005)
  • [9] Dykstra D., Enriquez A., Valley M., Treatment of overactive bladder with botulinum toxin type B: a pilot study, Int Urogynecol J Pelvic Floor Dysfunct, 14, pp. 424-426, (2003)
  • [10] Ghei M., Maraj B.H., Miller R., Nathan S., O'Sullivan C., Fowler C.J., Et al., Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial, J Urol, 174, pp. 1873-1877, (2005)
123